Spotlight On... WuXi and PRA canceling joint venture in China; Recipharm to manufacture LIDDS drug; Perrigo adds Retin-A portfolio; and more...

With WuXi PharmaTech concentrating on manufacturing and PRA Health Sciences ($PRAH) developing its own global strategy, the two companies have decided to split up their China-focused joint venture. Instead, they will have an alliance but will divide their operations in the country after more than two years of collaboration. Story

> Sweden's Recipharm will invest SEK 5 million in LIDDS as part of an agreement for the contract manufacturer to scale up for commercial production of LIDDS treatment candidate for prostate cancer. Release

> Perrigo ($PRGO) has reacquired a portfolio of generic Retin-A (tretinoin) products from Matawan Pharmaceuticals. Release

> Pharma's price-gouging poster boy Martin Shkreli was arrested by the FBI Thursday. Story

 

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.